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The Hydra 
by Carl E. Schneider 
A lmost nobody favors long consent forms for prospec-
tive research subjects. Almost 
everybody thinks they interfere with 
informed consent's purpose-good de-
cisions. Nevertheless, almost everybody 
believes consent forms have long been 
getting longer. 
Years ago, Paul Appelbaum lamented 
the "tendency to cram ever more infor-
mation into consent forms." 1 Weeks 
ago, Ilene Albala and her colleagues 
(one of them Appelbaum) reported in 
IRE: Ethics & Human Research that the 
length of one institutional review board's 
forms "increased roughly linearly by an 
average of 1. 5 pages per decade. In the 
1970s, the average consent form was 
less than one page long and often only a 
paragraph or two, but by the mid-1990s 
the average form had increased in length 
to over 4.5 pages." Similarly, "Baker 
and Taub demonstrated that the mean 
length of consent forms nearly doubled 
between 1975 and 1982. More recently, 
Beardsley and colleagues in Australia 
found that the median length of con-
sent forms increased from seven to 11 
pages between 2000 and 2005."2 
Long forms are deplored on sev-
eral grounds: That people will not read 
them. That even if people read them, 
they would not understand them. That 
even if people understood them, the 
forms would not promote better and 
might promote worse decisions. 
For example, in a study of prin-
cipal investigators, over half thought 
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contemporary consent forms "unlikely 
to be read" or "incomprehensible." 
Onerous length and detail that re-
duced subjects' understanding were be-
moaned. One researcher thought "most 
subjects skim through the incredibly 
long informed consents, believing that 
most of it is simply bureaucracy." 
These concerns are well founded. 
First, long forms repel, confuse, bore, 
and distract. (It appears "that, in an 
educational context, people are unlikely 
to read entire documents that contain 
more than 1000 words, or about 4 pag-
es."3) Furthermore, these forms com-
pete for your attention with hundreds 
of other disclosures about innumerable 
matters. Who could-who would-
study them all? Who reads credit card 
contracts, mortgage agreements, re-
tirement account prospectuses, bank 
privacy statements, online purchase 
conditions, HIPAA warnings, insurance 
provisions, or rental car forms?4 Not I. 
Not you. So, for example, the patients 
HIPAA blesses do "not appear to rec-
ognize, understand, or care about this 
complex law as it applies to research." 
They ask about disclosures "exceedingly 
rarely. For example, one academic health 
center reported that between 2003 and 
2007, the institution received only 23 
requests for accounting of disclosures, 
and none were from research." 5 
Second, in both research and clinical 
medicine even good forms and process-
es fail to achieve their educational goals. 
Even tested after optimal "consenting," 
patients correctly answer only a third to 
a half of the questions asked.6 And even 
patients with "a relatively large variety 
of information sources" use incorrect 
information, so that fewer than half the 
breast cancer patients in one study un-
derstood treatments' survival rates, and 
fewer than a fifth understood recurrence 
rates? The causes are many. For exam-
ple, illiteracy and innumeracy prevent 
many people from reading many forms. 
(Roughly ninety percent of the people 
in one study had at least some college 
education, but 40 percent "could not 
solve a basic probability problem or 
convert a percentage to a proportion. "8) 
Yet the simpler your language, the more 
words you need to explain your ideas, 
and the longer forms get. 
Third, people can keep only a few 
things in mind when analyzing a prob-
lem. Miller's "magical number seven" 
is the classic estimate, and it is easily 
exceeded. For example, Miranda warn-
ings are familiar, few, and short. Yet 
even with "verbal chunking" (combin-
ing data for easier storage) "the upper 
limit of information processing for 
Miranda warnings is likely less than 
75 words,"9 considerably fewer, that is, 
than the usual Miranda warning. And 
when anesthesiologists and nurse prac-
titioners tried to educate their patients, 
they "vastly exceeded patients' short-
term memory capacity."1° Furthermore, 
integrating "different types of informa-
tion and values into a decision is a very 
difficult cognitive process." Indeed, in-
formation can decrease the reliability of 
decisions. For example, the "reliability 
of the choices [of horse-racing handi-
cappers] decreased as more information 
was made available." 11 
If long forms are widely and rightly 
condemned, why do they keep getting 
longer and wronger? Each form must 
be individually approved by a regula-
tory agency-an IRB. This gives IRBs 
a degree of authority over disclosure few 
regulators can match. So if things are 
going wrong, IRBs are the first place to 
look for a cause. 
A study by William Burman (and 
others) provides a striking picture of 
how IRBs affect consent forms. 12 That 
study "evaluated the local review process 
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of two protocols from a multicenter 
clinical trials group." The twenty-five 
sites included "academic medical cen-
ters, Veteran's Administration Medical 
Centers, and public health departments 
chosen in large part for their experience 
in clinical research" and thus included 
"IRBs that are likely to be representa-
tive oflarge institutions oriented toward 
clinical research." IRB "review was a 
time-consuming process, requiring a 
median of 30 [range 10-48] hours of 
work by the local study site and more 
than 3 months of calendar time to 
complete." The IRBs did not require 
changes in the protocols, but they re-
quired a median of 46.5 changes in each 
consent form (range 3-160). (Only 1.5 
percent of the changes "were thought 
to represent a need to fit specific local 
conditions.") 
Most (85 percent) of the changes 
"did not change the meaning of the 
consent form," but they did change its 
quality. The forms got longer, the sen-
tences got wordier, the active voice got 
scarcer, and the reading-difficulty level 
got higher (by a mean of 0.9 levels), so 
that 41 percent of the forms "had an in-
appropriately high reading grade level." 
Furthermore, eleven percent of the 
changes actually introduced errors into 
the forms. Two-thirds of the forms "had 
an error of protocol presentation or a 
required consent form element." Many 
errors were minor, but over a quarter 
"were more substantive: deletions of sig-
nificant side effects (e.g., the possibility 
of hepatotoxicity from rifampin and/or 
pyrazinamide), major errors in the de-
scription of study procedures (e.g., in-
correct information on study duration), 
or the complete removal of a required 
section of the consent form (e.g., the 
right to withdraw from the study)." 
If this is how IRBs review consent 
forms, no wonder an old IRB hand like 
Robert Levine thinks "there is no more 
expensive or less competent redaction 
service available in the United States 
than that provided by an alarmingly 
large number ofiRBs." 13 But IRB mem-
bers surely share the preference for con-
cise consent forms. When a regulatory 
agency produces results neither it nor 
anyone else likes, there are deep-seated 
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reasons. We will consider three: the 
federal regulations, the IRB incentive 
structure, and the IRB system's goals. 
First, Appelbaum long ago cited 
"HHS Regulations . . . requiring that 
ever-increasing amounts of informa-
tion be presented to potential research 
subjects." 14 Certainly they demand co-
pious disclosures and invite IRBs to re-
quire more. Second, Vesuvian disclosure 
seems to protect IRBs and their institu-
tions against lawsuits and Office for Hu-
man Research Protections retribution. 
Third, such disclosure seems to serve 
the IRB system's goals. The Albala study 
found that "discrepancies in the descrip-
tions of risks between the consent form 
and the protocol" declined as forms' 
length increased. This might suggest 
that forms got longer because subjects 
needed more information. However, al-
though these discrepancies "had ceased 
before the end of our study window, 
page length continued to increase, sug-
gesting that greater attention to risks has 
not been the sole factor responsible for 
the increase in page length." 
The IRB system's goal is not just re-
porting risks described in a protocol. It 
is, as Appelbaum said, "full disclosure." 
This is an ever-expanding category, 
since new topics (like conflicts of inter-
est) and new risks (especially social, psy-
chological, and "dignitary'' risks) keep 
proliferating. And the goal is not just 
"full disclosure," but, as then-Secretary 
of Health and Human Services Donna 
Shalala announced, "maximal protec-
tion for all human subjects." Maximal 
means error free, since "even one lapse 
is too many." So in a 2,400-word ar-
ticle, Shalala used "ensure" nine times, 
"guarantee" twice, and "make sure" 
twice. The system must "guarantee" the 
"greatest possible protection for every 
human subject, in every clinical trial 
and at every research institution in the 
country." 15 
How are these utopian ambitions 
to be met? No doubt by yet more me-
ticulous forms, but also, the Institute of 
Medicine "urge[s, by] a new approach 
to informed consent, one in which le-
gal disclaimer and institutional self-
protection are second to clear, simple, 
unclouded, unhurried, and sensitive 
disclosure that gives the potential par-
ticipant all the information a reasonable 
person would need to make a well-
informed decision, and the time to do 
so." So "consent should be an ongoing 
process that focuses not on a written 
form or a static disclosure event, but 
rather on a series of dynamic conversa-
tions between the participant and the 
research staff that should begin before 
enrollment and be reinforced during 
each encounter or intervention." 16 And 
so an ever-more elaborate form becomes 
embedded in an ever-more elaborate 
process. 
But the giantism of consent forms is 
not just a product of the American IRB 
system. It is an international phenom-
enon. And it afflicts hundreds of other 
kinds of legally mandated disclosures. 
For example, the Truth in Lending 
Act of 1968 required lenders disclose 
interest rates and fees. Simple enough, 
perhaps, but soon the Federal Reserve 
issued Regulation Z to instruct credi-
tors. That regulation, "while it did not 
salvage Truth-In-Lending's basic goals, 
did succeed in making the statute too 
complex to be complied with." 17 
Giantism-in short-is inherent in 
conventional disclosure mandates like 
informed consent. They aspire to equip 
novices to make well-informed decisions 
about complex questions. Yet while less 
may be more, less is not enough. For 
the reasons we've canvassed, lengthy 
disclosures are self-defeating, but short-
er forms omit relevant facts. If there is 
a via media between too much and too 
little, it is elusive. 
Even if that via media could be 
found, the institutional dynamics of 
mandating disclosure-like the fear of 
legal liability, the threat of political criti-
cism, and ideological zeal-impel regu-
lators past moderation into excess. Long 
and ever-longer consent forms (and 
processes) we shall have always with us 
until we ask more basic questions about 
these mandates than we have dared face. 
Until then, prospective research subjects 
will be told much and learn little. 
1. P.S. Appelbaum, "Informed Consent: 
Always Full Disclosure?" in J .E. Sieber, NIH 
Readings on the Protection of Human Sub-
jects in Behavioral and Social Science Research: 
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